Regeneron Pharmaceuticals recently received U.S. FDA approval and a positive opinion from the European Medicines Agency's ...

The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody ...

The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and Sanofi to complete the approval process in one to two months.

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...

Regeneron Pharmaceuticals (REGN) has grabbed investor attention this week, as recent positive late-stage clinical data and a ...

The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on ...

Regeneron Pharmaceuticals' Libtayo won approval to treat certain patients with cutaneous squamous cell carcinoma, a type of skin cancer, from the Food and Drug Administration. The pharmaceutical ...

"Infertility treatment heads first drugs on FDA’s new priority review scheme" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

The FDA has approved Libtayo for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation.

Regeneron gests US FDA approval for Libtayo as an adjuvant treatment of CSCC with a high risk of recurrence after surgery and radiation: Tarrytown, New York Friday, October 10, 20 ...

Investing.com -- Regeneron Pharmaceuticals (NASDAQ:REGN) stock rose 2% Wednesday following the FDA’s approval of its drug Libtayo for the adjuvant treatment of adults with cutaneous squamous cell ...